The most common antiretroviral treatment (ART) received by individuals infected with HIV-1 in China is the combination therapy, comprised of nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). To assess the prevalence of HIV-1 drug resistance and subtypes in Honghe of Yunnan, China, patient plasmas from ART-failed individuals were collected from January 2010 to December 2012. Genotyping was conducted using an in-house assay on patient plasmas. A total of 254 pol sequences were obtained. The prevalence of drug resistance was 47.2% in ART-failed individuals. Of these drug-resistant individuals, 51.7% harbored HIV strains dually resistant to NRTIs and NNRTIs or protease inhibitors (PIs) (34.2% for NNRTIs and 14.2% for NRTIs). Mutations such as M184V, A62V, T69Ins, K103N, Y181C, and G190A were common among the ART-failed individuals. The frequencies of M184V, A62V, and K103N were 20.5%, 11.0%, and 23.6%, respectively. The most common subtypes in Honghe were CRF08_BC (68.50%) and CRF07_BC (12.20%). The subtypes were almost consistent in different time points for one individual. When receiving ART for 6–12 months, the frequency of HIV-1 drug-resistant variants ranked first. This study shows that the high prevalence of HIV drug resistance observed among the ART-failed individuals should be of increasing concern (monitoring of resistance mutations) in ART regions and facilitate developing novel strategies for prevention and control of HIV infection in China.
Get full access to this article
View all access options for this article.
References
1.
BroderS: The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res, 2010; 85:1–18.
2.
ChenM, MaY, DuanS, et al.: Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: A hot area of viral recombination in China. BMC Infect Dis, 2012; 12:382.
3.
ChowEP, WilsonDP, and ZhangL: What is the potential for bisexual men in China to act as a bridge of HIV transmission to the female population: Behavioural evidence from a systematic review and meta-analysis. BMC Infect Dis, 2011; 11:242.
4.
GarridoC, ZahoneroN, FernándesD, et al.: Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother, 2008; 61(3):694–698.
5.
GillVS, LimaVD, ZhangW, et al.: Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis, 2010; 50(1):98–105.
6.
HanXX, AnMH, ZhaoB, et al.: High prevalence of HIV-1 intersubtype B′/C recombinants among injecting drug users in Dehong, China. PLoS One, 2013; 8(5):e65337.
7.
HansonDL, Adje-ToureC, Talla-NzussouoN, et al.: HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses, 2009; 25:489–495.
8.
ImamichiT, BergSC, ImamichiH, et al.: Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69. J Virol, 2000; 74:10958–10964.
9.
JiaM, LuoH, MaY, et al.: The HIV epidemic in Yunnan province, China, 1989–2007. J Acquir Immune Defic Syndr, 2010; 53:S34–40.
10.
JuliasJG, BoyerPL, McWilliamsMJ, et al.: Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis. Virology, 2004; 322:13–21.
11.
LiHP, ZhongM, GuoW, et al.: Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan province, China. PLoS One, 2013; 8 (8):e72630.
12.
WangX, HeC, XingH, et al.: Emerging transmitted HIV type 1 drug resistance mutations among patients prior to start of first-line antiretroviral therapy in middle and low prevalence sites in China. AIDS Res Hum Retroviruses, 2012; 28(12):1637–1639.
13.
YangJ, XingH, NiuJL, et al.: The emergence of HIV-1 primary drug resistance genotypes among treatment-naive men who have sex with men in high-prevalence areas in China. Arch Virol, 2013; 158:839–844.
14.
XingH, RuanY, LiJ, et al.: HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients. PLoS One, 2013; 8(2):e54917.
15.
ZhangFJ: China Free ART Manual. Chinese Center for Disease Control and Prevention, Beijing, 2005, pp. 14–18.
16.
ZhangJ, KangDM, LinB, et al.: HIV type 1 virological response and prevalence of HIV type 1 drug resistance among patients receiving antiretroviral therapy, Shandong, China. AIDS Res Hum Retroviruses, 2012; 28(12):1658–1665.
17.
LiJ, LiuH, LiJ, et al.: Sexual transmissibility of HIV among opiates users with concurrent sexual partnerships: An egocentric network study in Yunnan, China. Addiction, 2011; 106:1780–1787.
18.
LiJY, LiHP, LiL, et al.: Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res, 2005; 15:843–849.
19.
LiaoL, XingH, DongY, et al.: Surveys of transmitted HIV drug resistance in 7 geographic regions in China, 2008–2009. Clin Infect Dis, 2012; 54:S320–323.
20.
LuoL and LiTS: Overview of antiretroviral treatment in China: Advancement and challenges. Chin Med J (Engl), 2011; 124:440–444.
21.
MaYL, ZhangY, LuL, et al.: The analysis of human immunodeficiency virus-1 subtypes in Yunnan province. Zhonghua Yu Fang Yi Xue Za Zhi, 2008; 42(12):892–894 (in Chinese).
22.
Martinez-PicadoJ and MartinezMA: HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res, 2008; 134:104–123.
23.
NikolenkoGN, PalmerS, MaldarelliF, et al.: Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA, 2005; 102:2093–2098.
24.
PillayV, PillayC, KantorR, et al.: HIV type 1 subtype C drug resistance among pediatric and adult south African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses, 2008; 24:1449–1454.
25.
PiyasirisilpS, McCutchanFE, CarrJK, et al.: A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol, 2000; 74 (23):11286–11295.
26.
SuL, GrafM, ZhangY, et al.: Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B′) recombinant strain in China. J Virol, 2000; 74(23):11367–11376.
27.
TeeKK, PybusOG, LiXJ, et al.: Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J Virol, 2008; 82(18):9206–9215.
28.
TsibrisAM and HirschMS: Antiretroviral therapy in the clinic. J Virol, 2010; 84:5458–5464.
29.
VolberdingPA and DeeksSG: Antiretroviral therapy and management of HIV infection. Lancet, 2010; 376:49–62.
30.
YangSM, FanYS, LiHQ, et al.: Investigation of pol gene variation of HIV-1 epidemic strains after treatment with HAART at Dehong prefecture and Kunming in Yunnan province. Chin J Lab Med, 2011; 34(4):315–320 (in Chinese).
31.
YangR, XiaX, KusagawaS, et al.: On-going generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan province of China. AIDS, 2002; 16(10):1401–1407.
32.
YangSM, ZhongM, YangBH, et al.: Drug resistance of AIDS antiviral treatment in Yunnan from 2008–2012. Chin J AIDS STD, 2014; 20(1):9–12 (in Chinese).
33.
ZhangFJ, PanJ, YuL, et al.: Current progress of China's free ART program. Cell Res, 2005; 15:877–882.
34.
ZhangKL and ZhouJS: Recapturing public health sciences for HIV/AIDS in China. Public Health, 2011; 125:266–268.
35.
ZhangY, LuL, BaL, et al.: Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med, 2006; 3(11):e443.
36.
ZhaoY, MuW, HarwellJ, et al.: Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: An observational cohort study in rural China. J Acquir Immune Defic Syndr, 2011; 58:47–53.
37.
ZhongM, YangBH, and YangSM: Analysis of genotype resistance mutations sites among 123 antiretroviral-therapy failure in HIV/AIDS patients in Yunnan province, China. Chin J Lab Med, 2013; 36(1):53–58 (in Chinese).
